SCHEMBL73997

SCHEMBL73997

CC(=O)[C@H](C)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL901230 1.00 TP53 (0.57) —
SCHEMBL42054 1.00 — —
SCHEMBL74607 1.00 — —
Hydrogen Peroxide SCHEMBL11422902 0.96 — —
Hydrochloric Acid SCHEMBL30716856 0.96 — —
Ammonia Solution, Strong SCHEMBL6545802 0.96 — —
Charcoal, Activated SCHEMBL12487647 0.96 — —
Isopropyl Alcohol SCHEMBL16321076 0.96 TP53 (0.53) —
SCHEMBL29399187 0.96 — —
Butanedione SCHEMBL2403188 0.92 TSHR (0.54) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119744885-A Application of Ace9 factor in enhancing activity of killing plant parasitic nematodes by using various bacillus 华中农业大学 2025-04-04 — — CN claimed
CN-119111525-A Liquid microbial agent containing small molecule microorganism-crop interaction signal substance and application thereof 中化农业(临沂)研发中心有限公司 2024-12-13 — — CN claimed
CN-117660389-A Transaminase mutant and application thereof in preparation of chiral amine compounds 浙江容锐科技有限公司 2024-03-08 — — CN claimed
CN-107129959-A Construction method and application of genetic engineering strain for producing (R) -acetoin 广西科学院 2017-09-05 — — CN claimed
US-20260021148-A1 METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOME BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2026-01-22 — — US disclosed
WO-2025245512-A1 METHODS TO SHIFT REDOX EQUILIBRIUM USING AN ORTHOGONAL REDOX COFACTOR, AND APPLICATIONS THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-11-27 — — WO disclosed
US-20250296907-A1 METHOD FOR OBTAINING ACETOIN LESAFFRE ET COMPAGNIE (FR) 2025-09-25 — — US disclosed
EP-4567123-A2 METHOD FOR PRODUCING L-AMINO ACID AJINOMOTO CO., INC. (JP) 2025-06-11 — — EP disclosed
US-12318413-B2 Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-06-03 — — US disclosed
US-12310996-B2 Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-05-27 — — US disclosed
CN-116254241-B 2, 3-Butanediol dehydrogenase mutant and application thereof 浙江大学杭州国际科创中心 2025-05-16 — — CN disclosed
CN-119744885-A Application of Ace9 factor in enhancing activity of killing plant parasitic nematodes by using various bacillus 华中农业大学 2025-04-04 — — CN disclosed
US-20080009435-A1 Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them PHARMA MAR, S.A., A SPAIN CORPORATION 2008-01-10 — — US disclosed
WO-2007143745-A2 SUBSTITUTED PHENYL ACETIC ACIDS AS DP-2 ANTAGONISTS ICOS CORPORATION (US) 2007-12-13 — — WO disclosed
US-20070244158-A1 Piperdine Compound and Process for Preparing the Same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-10-18 — — US disclosed
US-20070244158-A1 Piperdine Compound and Process for Preparing the Same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-10-18 — — US disclosed
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 — — US disclosed
US-20070078146-A1 Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma PHARMACIA CORPORATION 2007-04-05 — — US disclosed
US-20070043009-A1 Quinazoline derivatives as tyrosine kinase inhibitors ASTRAZENECA AB (SE) 2007-02-22 — — US disclosed
WO-2006007700-A1 HEPATITIS C INHIBITOR DIPEPTIDE ANALOGS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-01-26 — — WO disclosed
Send feedback